Goal 2: Reduce Human Disease

Nontuberculous mycobacterial (NTM) lung infections

The true prevalence of Nontuberculous mycobacterial (NTM) lung infections remains incompletely understood, however several aspects of NTM lung disease prevalence are becoming more clear. NTM lung disease is currently more common in the U.S. than TB (by a factor of 3) and has consistently been shown to be increasing in prevalence. When viewed in the context of likely universal environmental NTM exposure this increasing ...more »

Submitted by (@nhlbiforumadministrator)

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 1: Promote Human Health

Crowdsource NIH Funding

Congress doesn't seem to "get it" regarding the return on investment for biomedical research, but maybe the public does. Create a mechanism whereby individuals can donate directly to the NIH to support research in specific areas (or provide general support).

Submitted by (@jhagood)

Voting

21 net votes
29 up votes
8 down votes
Active

Goal 2: Reduce Human Disease

Clinical trials of AAT augmentation therapy

Alpha-1 antitrypsin augmentation therapy is widely used for PI ZZ subjects, but randomized clinical trials of AAT augmentation therapy have not been adequately powered to assess the efficacy of this treatment. A clinical trial using COPD exacerbation frequency as the primary outcome, rather than decline in lung function, in PI ZZ subjects with moderate-to-severe COPD could provide definitive evidence for the utility of ...more »

Submitted by (@nhlbiforumadministrator)

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Developing adherence research to reduce unnecessary mobility/mortality/cost

From Cochrane Review NOV 20 2014 RB Haynes “It is uncertain how medicine adherence can consistently be improved so that the full health benefits of medicines can be realized. We need more advanced methods for researching ways to improve medicine adherence, including better interventions, better ways of measuring adherence, and studies that include sufficient patients to draw conclusions on clinically important effects.” ...more »

Submitted by (@nhlbiforumadministrator)

Voting

5 net votes
7 up votes
2 down votes
Active

Goal 1: Promote Human Health

Improve understanding of cardiometabolic health in Asian Americans

We are only now beginning to recognize that certain Asian American subpopulations are at high risk for cardiometabolic (CM) disorders thanks to recent ethnicity-specific studies (e.g., MASALA study). For the most part, however, our understanding of CM risk in Asian Americans is based on aggregated data. Further, a perception remains that other, understudied groups (e.g., Chinese Americans) are at low risk because of their ...more »

Submitted by (@mtseng)

Voting

1 net vote
5 up votes
4 down votes
Active

Goal 2: Reduce Human Disease

Innovations in Red Cell Transfusion in Sickle Cell Disease

Challenges that need to be overcome in blood transfusion, especially in SCD, include: a. Adopting molecular genotyping as the standard in blood transfusion therapy. b. Advancing new generation, anti-oxidant hemoglobin-based oxygen carriers (HBOCs) for use in emergencies such as trauma, stroke, acute hemolysis, and in transfusion in SCD and related disorders. In SCD, HBOCs have the capacity to not only serve as substitutes ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

29 net votes
47 up votes
18 down votes
Active